Method for treating or preventing inflammatory diseases
AssigneeInspire Pharmaceuticals, Inc.
InventorsWard M. Peterson, Benjamin R. Yerxa
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of preventing or treating an inflammatory disease, including but not limited to, sinusitis, rhinitis, conjunctivitis, asthma, dermatitis, inflammatory bowel disease, inflammatory collagen vascular diseases, glomerulonephritis, inflammatory skin diseases, and sarcoidosis. The method comprises administrating to a subject a pharmaceutical formulation comprising a nucleotide receptor agonist, such as nucleoside diphosphate, nucleoside triphosphate, or dinucleoside polyphosphate, according to general formula Ia, Ib, IIa, IIb, or III. Preferred indications of the present invention are perennial allergic rhinitis, seasonal allergic rhinitis, infectious allergic rhinitis, and allergic conjunctivitis.
Claims18
A method of treating an inflammatory disease, said method comprising:
- administering to a subject suffering from an inflammatory disease a pharmaceutical formulation comprising a P2Y receptor agonist in an amount effective to treat the inflammatory disease, wherein said inflammatory disease is selected from the group consisting of rhinitis, conjunctivitis, asthma, dermatitis, inflammatory bowel disease, inflammatory collagen vascular diseases, glomerulonephritis, inflammatory skin diseases, sarcoidosis, and an inflammatory disease caused by infection or allergy, wherein said P2Y receptor agonist is a dinucleoside polyphosphate where the polyphosphate is in between the two nucleosides.
A method of treating an inflammatory disease, said method comprising:
- administering to a subject a pharmaceutical formulation comprising a P2Y receptor agonist in an amount effective to treat the inflammatory disease, whereis said P2Y receptor agonist is a dinucleoside triphosphate selected from the group consisting of:
- P1P3-di(uridine 5′-)triphosphate;
- P1-(cytosine 5′)-P3-(uridine 5′-)triphosphate;
- P1,P3-di(adenosine 5′-)triphosphate;
- P1-(adenosine 5′)-P3-(uridine 5′-)triphosphate;
- P1-(adenosine 5′)-P3-(cytosine 5′-)triphosphate;
- P1,P3-di(ethenoadenosine)triphosphate;
- P1-(uridine 5′)-P3-(thymidine 5′-)triphosphate;
- P1-(adenosine 5′)-P3-(inosine 5 ′-)triphosphate;
- P1,P3-di(uridine 5′-)P2,P3-methylenetriphosphate;
- P1,P3-di(uridine 5′-P2,P3-difluoromethylenetriphosphate);
- P1,P3-di(uridine 5′-P2,P3-imidotriphosphate);
- P1,P3-di(4-thiouridine 5′-triphosphate);
- P1,P3-di(3,N4-ethenocytidine 5′-)triphosphate;
- P1,P3-di(imidazo[1,2-c]pyrimidine-5(6H)-one-2-(3-nitro)-phenyl-6-β-D-ribofuranoside 5′-)triphosphate;
- P1-(inosine 5′-)P3-(uridine 5′-)triphosphate;
- P1-(4-thiouridine 5′-)P3-(uridine 5′-)triphosphate;
- P1-(cytosine β-D-arabinofuranoside 5′-)P3-(uridine 5′)triphosphate;
- P1-(uridine 5′-)P3-(xanthosine 5′-)triphosphate;
- P1-(2′-deoxyuridine 5′-)-P3-(uridine 5′-)triphosphate;
- P1-(3′-azido-3′-deoxythymidine 5′-)-P3-(uridine 5′-)triphosphate;
- P1,P3-di(3′-azido-3′-deoxythymidine 5′-)triphosphate;
- 2′(3′)-benzoyl-P1,P3-di(uridine 5′-)triphosphate;
- P1,P3-di(2′,3′-benzoyl uridine 5′-)triphosphate;
- P′-(2′-deoxyguanosine 5′-)P3-(uridine 5′-)triphosphate;
- P1-(2′-deoxyadenosine 5′-)P3-(uridine 5′-)triphosphate;
- P1-(2′-deoxyinosine 5′-)P3-(uridine 5′-)triphosphate;
- P1-(2′-deoxycytidine 5′-)P3-(uridine 5′-)triphosphate;
- P1-(4-thiouridine 5′-) P3-(uridine 5′-) triphosphate;
- P1-(8-azaadenosine-5 ′-)P3-(uridine 5′-)triphosphate;
- P1-(6-mercaptopurine riboside 5′-)P3-(uridine 5′-)triphosphate;
- P1-(6-mercaptopurine riboside 5′-) P3-(2′-deoxyuridine 5′-)triphosphate;
- P1-(4-thiouridine 5′-)P3-(arabinocytidine 5′-)triphosphate;
- P1-(adenosine 5′-) P3-(4-thiomethyluridine 5′-)triphosphate;
- P1-(2′-deoxyadenosine 5′-)P3-(6-thiohexylpurine riboside 5′-)tetraphosphate;
- and P1-(6-eicosanyloxypurine riboside 5′-)P3-(uridine 5′-)triphosphate.
A method of treating an inflammatory disease, said method comprising:
- administering to a subject a pharmaceutical formulation comprising a P2Y receptor agonist in an amount effective to treat the inflammatory disease, wherein said P2Y receptor agonist is selected from the group consisting of:
- P1-(uridine 5′-)P2-(4-thiouridine 5′-)diphosphate;
- P1,P5-di(uridine 5′-)pentaphosphate;
- and P1,P6-di(uridine 5′-)hexaphosphate.
Dependencies are inferred from the claim text.